BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36142502)

  • 1. Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics.
    Krencz I; Vetlényi E; Dankó T; Petővári G; Moldvai D; Sztankovics D; Raffay R; Mészáros K; Sebestyén E; Végső G; Pápay J; Sebestyén A
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Papillary renal cell carcinoma and clear cell renal cell carcinoma: Differentiation of distinct histological types with contrast - enhanced ultrasonography.
    Xue LY; Lu Q; Huang BJ; Li Z; Li CX; Wen JX; Wang WP
    Eur J Radiol; 2015 Oct; 84(10):1849-56. PubMed ID: 26149528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma.
    Takahashi H; Vikram R; Jimenez RE; Bolan CW; Kawashima A; Karam JA; Takahashi N
    Abdom Radiol (NY); 2021 Nov; 46(11):5250-5259. PubMed ID: 34338814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate.
    Nilsson H; Lindgren D; Mandahl Forsberg A; Mulder H; Axelson H; Johansson ME
    Cell Death Dis; 2015 Jan; 6(1):e1585. PubMed ID: 25569102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
    Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
    Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
    Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
    Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
    Zhao H; Leppert JT; Peehl DM
    PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free-Fatty Acid Receptor-4 (FFA4/GPR120) differentially regulates migration, invasion, proliferation and tumor growth of papillary renal cell carcinoma cells.
    Karmokar PF; Moniri NH
    Biochem Pharmacol; 2023 Jul; 213():115590. PubMed ID: 37201877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro.
    Zieren RC; Dong L; Clark DJ; Kuczler MD; Horie K; Moreno LF; Lih TM; Schnaubelt M; Vermeulen L; Zhang H; de Reijke TM; Pienta KJ; Amend SR
    Med Oncol; 2021 Jul; 38(9):105. PubMed ID: 34331598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment.
    Tachibana H; Inakawa T; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Anticancer Res; 2022 Jun; 42(6):3151-3158. PubMed ID: 35641290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
    Halefoglu AM; Ozagari AA
    Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma.
    Wang Q; Zhang Y; Zhang B; Fu Y; Zhao X; Zhang J; Zuo K; Xing Y; Jiang S; Qin Z; Li E; Guo H; Liu Z; Yang J
    Nat Commun; 2022 Jan; 13(1):31. PubMed ID: 35013217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
    Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
    PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
    Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of renal cell carcinoma subtypes through MRI-based radiomics analysis.
    Wang W; Cao K; Jin S; Zhu X; Ding J; Peng W
    Eur Radiol; 2020 Oct; 30(10):5738-5747. PubMed ID: 32367419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.